In this episode of the WTR Healthcare Happenings podcast, Water Tower Research’s Shawn Severson and Robert Sassoon are joined by Dr. Paul Sargeant, President and CEO of Circular Genomics, a privately held molecular diagnostics company developing next‑generation blood tests based on circular RNA biomarkers. The conversation explores the science behind circular RNA, the company’s product pipeline, including the pursuit of an out‑licensing strategy, depression assay strategy, and a planned late-2026 launch of its Alzheimer’s research-use-only (RUO) assay; its systems‑level approach to Alzheimer's beyond the amyloid‑tau model; Circular Genomics’ commercialization plans, funding strategy, and long-term exit strategy goal.
